The Immune Atlas identifies immune signatures in MM, enhancing outcome prediction and guiding personalized therapies by ...
Meet the Jekyll and Hyde of the immune system: activated CD8⁺ T cells. On June 24 in Nature Immunology, researchers led by Dorian McGavern at the National Institutes of Health introduce a granzyme ...
CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...
TG4050 elicits strong polyepitopic, polyclonal, durable cytotoxic and effector neoantigen-specific CD8 T cell responses Results reinforce TG4050 ...
Immune checkpoint blockade therapy relies on releasing a natural brake in the immune system to fight cancer. This therapy activates the body’s CD8+ cytotoxic T cells, which mount an attack against ...
Higher levels of CD4-positive naïve T cells in patients receiving CAR T-cell therapy for multiple myeloma are associated with ...
Purpose: The permeability of 13 different gloves to 13 cytotoxic agents under controlled dynamic conditions is described. Methods: Thirteen cytotoxic agents were prepared at the highest concentrations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback